Araris Biotech

company

About

Araris Biotech is a biotechnology platform enables the attachment of any payload to ‘off the shelf’ antibodies.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$24M
Industries
Biotechnology,Health Care
Founded date
Jan 1, 2019
Number Of Employee
1 - 10
Operating Status
Active

Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$24M
Araris Biotech has raised a total of $24M in funding over 2 rounds. Their latest funding was raised on Oct 4, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 4, 2022 Series A $24M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Araris Biotech is funded by 1 investors. Wille AG are the most recent investors.
Investor Name Lead Investor Funding Round
Wille AG Series A